Intermediate for Carfilzomib. Carfilzomib (trade name: Kyprolis) is an anti-cancer drug acting as a selective proteasome inhibitor. Carfilzomib has been approved by the U.S Food and Drug Administration on July 20, 2012.
Product Name: (S)-Benzyl 2-((S)-2-amino-4-methylpentanamido)-3-phenylpropanoate hydrochloride
CAS Number: 70691-56-4
Molecular Weight:  404.9357
Molecular Formula:  C22H29ClN2O3
Purity (HPLC): ≥95%
Shipping Conditions: Room temperature.
Storage Conditions: Refrigerated.
Regulatory Statement:  For Research Use Only.